Pfizer Stock News

Despite recent declines, the Dividend Harvesting Portfolio remains profitable, generating $1,908.79 in forward dividend income with a 23.38% return on invested capital. I believe the Fed's rate cuts are misplaced, and lower rates are needed to reduce housing costs and further curb inflation. I am bullish on 2025, expecting the portfolio to generate between $2,500-3,000 in dividend income, drive...

You can pat yourself on the back if you're thinking of loading up your portfolio with dividend-paying stocks -- because they're surprisingly strong wealth builders. (If you weren't thinking of doing so, you can start now!

High-yield dividend stocks often catch investors' attention -- and for good reason. When established companies maintain larger-than-average dividend payments, they can provide both substantial current income and the potential for long-term appreciation.

I'm not a fan of New Year's Eve or market predictions. To shift the focus, I asked followers to select a single stock for a 10-year investment horizon. The responses were intriguing, ranging from a defensive giant to a high-growth sector leader. I analyzed each pick, considering their long-term prospects and potential for outperformance. Whether facing economic uncertainty or market volatility,...

If you haven't finished your Christmas shopping yet, you're rapidly running out of time. I suspect many people have already purchased most of the gifts they'll give but might still have a few remaining.

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's valuation at 9x 2025 EPS and a 6.5% dividend yield make it attractive for long-term investors. Management's 2025 guidance indicates flat sales but improved profitability, with gross margins expected to reach t...

Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (PFE 2.29%) is communicating that everything is under control. Per its updated forecast for its 2024 and 2025 fiscal years on Dec. 17, the overarching message is that the pharma will continue to seek to control its costs while bolstering i...

Stock market investors have plenty of reasons to celebrate as 2024 comes to a close. The S&P 500 index set multiple new record highs during the year, delivering a spectacular 25% return year to date amid a resilient economy and strong corporate earnings.